X0306 4 2021-08-05 0 0001863294 DA32 Life Science Tech Acquisition Corp. DALS 0001472624 Wolfe Chris DA32 LIFE SCIENCE TECH ACQUISITION CORP 345 PARK AVENUE SOUTH, 12TH FLOOR NEW YORK NY 10010 0 1 0 0 Chief Financial Officer Class B Common Stock, par value $0.0001 per share 2021-08-05 4 D 0 18750 0.00 D Class A Common Stock 18750 125000 D The shares of Class B Common Stock are convertible into shares of the Issuer's Class A Common Stock as described under the heading "Description of Shares" in the Issuer's Registration Statement on Form S-1 (File No. 333-257679) (the "Registration Statement") and have no expiration date. On August 5, 2021, the Reporting Person forfeited 18,750 shares of Class B Common Stock to the Issuer for no consideration, which was exempted pursuant to Rule 16b-3(e) under the Securities Exchange Act of 1934, as amended, in connection with the underwriters' election to forfeit their overallotment option on August 4, 2021. The forfeiture was not within the Reporting Person's control as it occurred exclusively due to the underwriters' decision not to exercise the overallotment option and occurred shortly after the Issuer filed the final statutory prospectus for the initial public offering (the "IPO") disclosing all material information about the Issuer and the IPO. Henrikki Harsu, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 3 with regard to DA32 Life Science Tech Acquisition Corp. filed with the Securities and Exchange Commission on July 27, 2021 by Chris Wolfe. /s/ Henrikki Harsu, Attorney-in-Fact for Chris Wolfe 2021-08-09